Inovio Pharmaceuticals (NYSE:INO) CEO Jong Joseph Kim purchased 25,000 shares of the stock in a transaction dated Tuesday, April 15th. The stock was purchased at an average cost of $2.25 per share, for a total transaction of $56,250.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,965,809 shares in the company, valued at approximately $13,423,070. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) shares after opening at $2.68 moved to $2.68 on last trade day and at the end of the day closed at $2.60. Company price to sales ratio in past twelve months was calculated as 46.25 and price to cash ratio as 11.87. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) showed a negative weekly performance of -2.62%.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Director Bruce Kovner bought 1,250,000 shares of Synta Pharmaceuticals Corp. stock on the open market in a transaction dated Friday, April 11th. The shares were purchased at an average price of $4.01 per share, for a total transaction of $5,012,500.00. Following the acquisition, the director now directly owns 3,048,666 shares in the company, valued at approximately $12,225,151. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) shares fell -0.95% in last trading session and ended the day on $4.15. SNTA return on equity ratio is recorded as -231.70% and its return on assets is -112.90%. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) yearly performance is -57.52%.
Repligen Corporation (NASDAQ:RGEN)’s SVP Daniel P Witt buy 10000 shares of RGEN in a transaction dated on April 15, 2014. Repligen Corporation (NASDAQ:RGEN) shares were bought at an average price of $3.05 for total worth of $30,500.00. Repligen Corporation (NASDAQ:RGEN) shares moved down -1.14% in last trading session and was closed at $15.66, while trading in range of $14.92 – $15.96. Repligen Corporation (NASDAQ:RGEN) year to date (YTD) performance is 14.81%.
Oramed Pharmaceuticals (NASDAQ:ORMP) major shareholder Regals Capital Management Lp bought 75,000 shares of the stock on the open market in a transaction dated Tuesday, March 25th. The stock was purchased at an average price of $10.62 per share, for a total transaction of $796,500.00. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) weekly performance is -0.24%. On last trading day company shares ended up $12.51. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) distance from 50-day simple moving average (SMA50) is -4.84%. Analysts mean target price for the company is $31.00.